|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ng L, Poon RT and Pang R: Biomarkers for
predicting future metastasis of human gastrointestinal tumors. Cell
Mol Life Sci. 70:3631–3656. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Girard JP and Springer TA: Cloning from
purified high endothelial venule cells of hevin,a close relative of
the antiadhesive extracellular-matrix protein SPARC. Immunity.
2:113–123. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hambrock HO, Nitsche DP, Hansen U,
Bruckner P, Paulsson M, Maurer P and Hartmann U: SC1/hevin. An
extracellular calcium-modulated protein that binds collagen I. J
Biol Chem. 278:11351–11358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Isler SG, Schenk S, Bendik I, Schraml P,
Novotna H, Moch H, Sauter G and Ludwig CU: Genomic organization and
chromosomal mapping of SPARC-like 1, a gene down regulated in
cancers. Int J Oncol. 18:521–526. 2001.PubMed/NCBI
|
|
6
|
Bendik I, Schraml P and Ludwig CU:
Characterization of MAST9/Hevin, a SPARC-like protein, that is
down-regulated in non-small cell lung cancer. Cancer Res.
58:626–629. 1998.PubMed/NCBI
|
|
7
|
Lau CP, Poon RT, Cheung ST, Yu WC and Fan
ST: Sparc and hevin expression correlate with tumour angiogenesis
in hepatocellular carcinoma. J Pathol. 210:459–468. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Claeskens A, Ongenae N, Neefs JM, Cheyns
P, Kaijen P, Cools M and Kutoh E: Hevin is down-regulated in many
cancers and is a negative regulator of cell growth and
proliferation. Br J Cancer. 82:1123–1130. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu H, Zhang H, Ge W, et al: Secreted
protein acidic and rich in cysteines-like 1 suppresses
aggressiveness and predicts better survival in colorectal cancers.
Clin Cancer Res. 18:5438–5448. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and
Zheng S: SPARC1, Shp2, MSH2, E-cadherin, p53, ADCY-2, and MAPK are
prognosis-related in colorectal cancer. World J Gastroenterol.
17:2028–2036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Widegren E, Wang DW and Sun XF:
SPARCL1: A potential molecule associated with tumor diagnosis,
progression and prognosis of colorectal cancer. Tumour Biol.
32:1225–1231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kotti A, Holmqvist A, Albertsson M and Sun
XF: SPARCL1 expression increases with preoperative radiation
therapy and predicts better survival in rectal cancer patients. Int
J Radiat Oncol Biol Phys. 88:1196–1202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao F, Wang K, Zhu R, Hu YW, Fang WZ and
Ding HZ: Clinicopathological significance of reduced SPARCL1
expression in human breast cancer. Asian Pac J Cancer Prev.
14:195–200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jakharia A, Borkakoty B and Singh S:
Expression of SPARC like protein 1 (SPARCL1), extracellular
matrix-associated protein is down regulated in gastric
adenocarcinoma. J Gastrointest Oncol. 7:278–283. 2016.PubMed/NCBI
|
|
15
|
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann
BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, et al:
SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol.
7:1019–1030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Isler SG, Ludwig CU, Chiquet-Ehrismann R
and Schenk S: Evidence for transcriptional repression of SPARC-like
1, a gene downregulated in human lung tumors. Int J Oncol.
25:1073–1079. 2004.PubMed/NCBI
|
|
17
|
Lerebours F, Olschwang S, Thuille B,
Schmitz A, Fouchet P, Buecher B, Martinet N, Galateau F and Thomas
G: Fine deletion mapping of chromosome 8p in non-small-cell lung
carcinoma. Int J Cancer. 81:854–858. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li P, Qian JX, Yu GZ, Chen Y, Liu K, Li J
and Wang J: Down-regulated SPARCL1 is associated with clinical
significance in human gastric cancer. J Surg Oncol. 105:31–37.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bradshaw AD: Diverse biological functions
of the SPARC family of proteins. Int J Biochem Cell Biol.
44:480–488. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu QZ, Gao XH, Chang WJ, Wang HT, Wang H,
Cao GW and Fu CG: Secreted protein acidic and rich in cysteine
expression in human colorectal cancer predicts postoperative
prognosis. Eur Rev Med Pharmacol Sci. 19:1803–1811. 2015.PubMed/NCBI
|
|
21
|
Wang Z, Hao B, Yang Y, Wang R, Li Y and Wu
Q: Prognostic role of SPARC expression in gastric cancer: A
meta-analysis. Arch Med Sci. 10:863–869. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Esposito I, Kayed H, Keleg S, Giese T,
Sage EH, Schirmacher P, Friess H and Kleeff J: Tumor-suppressor
function of SPARC-like protein 1/Hevin in pancreatic cancer.
Neoplasia. 9:8–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han W, Cao F, Chen MB, Lu RZ, Wang HB, Yu
M, Shi CT and Ding HZ: Prognostic value of SPARC in patients with
pancreatic cancer: A systematic review and meta-analysis. Plos One.
11:e01458032016. View Article : Google Scholar : PubMed/NCBI
|
